I-mab share price logo

I-mab Share Price

NASDAQ: IMAB

$4.64

as on

Bell Icon

The stock has been delisted from the stock exchange on 28 Oct 2025

I-mab Stock Performance

as on October 30, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $4.5
    $4.76
    downward going graph

    3.02%

    Downside

    2.59%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.6
    $6.79
    downward going graph

    87.18%

    Downside

    46.34%

    Upside

    downward going graph

I-mab share price movements today

Previous Close
$4.64
Open
$4.70
Volume
1.1M
Day's Low - High
$4.5 - $4.76
52 Week Low - High
$0.6 - $6.79

I-mab Historical Returns

1 Month Return
0 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

I-mab Stock Fundamentals & Key Indicators

Check I-mab market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$-

EPS (TTM)

0

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

0.00%

I-mab vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of I-mab with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
I-mab image
I-mab
BUY$-NANA0.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$62.4B291.63%-505.15-12.96%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$36.4BNANA-3.89%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$108.3B100.24%30.0231.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$69.4B20.12%15.732.13%

Analyst Recommendation on I-mab Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for I-mab. Average target price of $8.6

I-mab Share Price Target

Get share price movements and forecasts by analysts on I-mab.

What analysts predicted

46.05%UPSIDE

Target Price

$8.6

Current Price

$4.64

Analyzed by

11 Analysts

Target

$8.60

I-mab target price $8.6, a slight upside of 46.05% compared to current price of $4.64. According to 11 analysts rating.

I-mab Stock’s Investor Sentiment and Interest

Search interest for I-mab Stock has increased by 84% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:84% versus previous 30 day period

I-mab Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
1
9
3
3
1
-
-
-
-
-
Gross Profit
1
9
3
-
-19
-
-
-
-
-
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-56
-386
-346
-66
20
25
-20
-9
-3
-5
Net Profit Margin
-3931.80%
-3931.80%
-8673.15%
-2045.32%
1835.25%
0.00%
0.00%
0.00%
0.00%
0.00%

I-mab Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
1
7
4
235
13
-1
0
-
Gross Profit
1
7
4
235
6
-35
0
-
Operating Income
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
Net Income
-45
-58
-211
71
-366
-359
-205
-162
Net Profit Margin
-2580.82%
-749.02%
-4950.00%
30.53%
-2648.70%
23438.90%
-32674.02%
0.00%

Global Institutional Holdings in I-mab

Funds
Holdings
Hillhouse Capital Advisors, Ltd.
7.32%
Candriam Luxembourg S.C.A.
1.39%
SG Americas Securities, LLC
1.07%
Two Sigma Advisers, LLC
0.26%
UBS Group AG
0.23%
See all

I-mab News & Key Events

  • img

    Today's Timeline - 29 October

    Thu, 02:03 AM

    -

    I-MAB officially changes its name to NovaBridge Biosciences, with new ticker NBP effective October 30, 2025.

Insights on I-mab

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, IMAB stock has moved up by 5.7%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, IMAB has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 132.7% return, outperforming this stock by 112.5%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -3.15M → -5.50M (in $), with an average decrease of 74.7% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 4 quarters, 9.82M → 1.13M (in $), with an average decrease of 47.6% per quarter

About I-mab

I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
OrganisationI-mab
E-voting on sharesClick here to vote

FAQs

What is I-mab share price today?

I-mab share price today is $4.64 as on at the close of the market. I-mab share today touched a day high of $4.76 and a low of $4.5.

What is the 52 week high and 52 week low for I-mab share?

I-mab share touched a 52 week high of $6.79 on and a 52 week low of $0.6 on . I-mab stock price today i.e. is closed at $4.64,which is 31.66% down from its 52 week high and 679.83% up from its 52 week low.

How to invest in I-mab Stock (IMAB) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for I-mab on INDmoney app. Click on Buy button. You can invest as low as $1.5 in I-mab Shares that will get you 0.3233 shares as per I-mab share price of $4.64 per share as on October 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy I-mab Stock (IMAB) from India?

Indian investors can start investing in I-mab (IMAB) shares with as little as ₹88.686 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹886.86 in I-mab stock (as per the Rupee-Dollar exchange rate as on ). Based on I-mab share’s latest price of $4.64 as on October 30, 2025 at 1:29 am IST, you will get 2.1552 shares of I-mab. Learn more about fractional shares .